Research advances in aptamers in the diagnosis and treatment of breast cancer (Review)
International Journal of Oncology · 2026
DOI: 10.3892/ijo.2026.5885 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, 2026. Verfasst von Liqiang Chu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Graduate, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Graduate, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China.
- School of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China.
- Department of Scientific Research, Breast Cancer Center, Affiliated Cancer Hospital of Inner Mongolia Medical University/Peking University Cancer Hospital (Inner Mongolia Campus), Hohhot, Inner Mongolia Autonomous Regio…
Zitieren
APA
Chu, L., Xiao, Y., Li, X., Cui, J., Ma, L., Shao, B., & Cui, H. (2026). Research advances in aptamers in the diagnosis and treatment of breast cancer (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2026.5885
Vancouver
Chu L, Xiao Y, Li X, Cui J, Ma L, Shao B, et al. Research advances in aptamers in the diagnosis and treatment of breast cancer (Review). International Journal of Oncology. 2026. doi:10.3892/ijo.2026.5885
BibTeX
@article{Chu2026,
author = {Chu, Liqiang and Xiao, Yunfeng and Li, Xinhua and Cui, Jiawei and Ma, Luyao and Shao, Bin and Cui, Hongwei},
title = {Research advances in aptamers in the diagnosis and treatment of breast cancer (Review)},
journal = {International Journal of Oncology},
year = {2026},
doi = {10.3892/ijo.2026.5885}
}
EUVIMED